268 related articles for article (PubMed ID: 24023285)
1. Efficacy of liposomal curcumin in a human pancreatic tumor xenograft model: inhibition of tumor growth and angiogenesis.
Ranjan AP; Mukerjee A; Helson L; Gupta R; Vishwanatha JK
Anticancer Res; 2013 Sep; 33(9):3603-9. PubMed ID: 24023285
[TBL] [Abstract][Full Text] [Related]
2. Determination of minimum effective dose and optimal dosing schedule for liposomal curcumin in a xenograft human pancreatic cancer model.
Mach CM; Mathew L; Mosley SA; Kurzrock R; Smith JA
Anticancer Res; 2009 Jun; 29(6):1895-9. PubMed ID: 19528445
[TBL] [Abstract][Full Text] [Related]
3. Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis.
Li L; Braiteh FS; Kurzrock R
Cancer; 2005 Sep; 104(6):1322-31. PubMed ID: 16092118
[TBL] [Abstract][Full Text] [Related]
4. Liposome-encapsulated curcumin suppresses growth of head and neck squamous cell carcinoma in vitro and in xenografts through the inhibition of nuclear factor kappaB by an AKT-independent pathway.
Wang D; Veena MS; Stevenson K; Tang C; Ho B; Suh JD; Duarte VM; Faull KF; Mehta K; Srivatsan ES; Wang MB
Clin Cancer Res; 2008 Oct; 14(19):6228-36. PubMed ID: 18829502
[TBL] [Abstract][Full Text] [Related]
5. Molecular evidences for the chemosensitizing efficacy of liposomal curcumin in paclitaxel chemotherapy in mouse models of cervical cancer.
Sreekanth CN; Bava SV; Sreekumar E; Anto RJ
Oncogene; 2011 Jul; 30(28):3139-52. PubMed ID: 21317920
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic effects of a novel synthetic curcumin analogue in pancreatic cancer.
Nagaraju GP; Zhu S; Ko JE; Ashritha N; Kandimalla R; Snyder JP; Shoji M; El-Rayes BF
Cancer Lett; 2015 Feb; 357(2):557-65. PubMed ID: 25497868
[TBL] [Abstract][Full Text] [Related]
7. Curcumin sensitizes human colorectal cancer xenografts in nude mice to gamma-radiation by targeting nuclear factor-kappaB-regulated gene products.
Kunnumakkara AB; Diagaradjane P; Guha S; Deorukhkar A; Shentu S; Aggarwal BB; Krishnan S
Clin Cancer Res; 2008 Apr; 14(7):2128-36. PubMed ID: 18381954
[TBL] [Abstract][Full Text] [Related]
8. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
9. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB in breast cancer cells and potentiates the growth inhibitory effect of paclitaxel in a breast cancer nude mice model.
Kang HJ; Lee SH; Price JE; Kim LS
Breast J; 2009; 15(3):223-9. PubMed ID: 19645775
[TBL] [Abstract][Full Text] [Related]
10. Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma.
Stover TC; Sharma A; Robertson GP; Kester M
Clin Cancer Res; 2005 May; 11(9):3465-74. PubMed ID: 15867249
[TBL] [Abstract][Full Text] [Related]
11. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice.
Aggarwal BB; Shishodia S; Takada Y; Banerjee S; Newman RA; Bueso-Ramos CE; Price JE
Clin Cancer Res; 2005 Oct; 11(20):7490-8. PubMed ID: 16243823
[TBL] [Abstract][Full Text] [Related]
12. A liposomal formulation of the synthetic curcumin analog EF24 (Lipo-EF24) inhibits pancreatic cancer progression: towards future combination therapies.
Bisht S; Schlesinger M; Rupp A; Schubert R; Nolting J; Wenzel J; Holdenrieder S; Brossart P; Bendas G; Feldmann G
J Nanobiotechnology; 2016 Jul; 14(1):57. PubMed ID: 27401816
[TBL] [Abstract][Full Text] [Related]
13. Nestin as a novel therapeutic target for pancreatic cancer via tumor angiogenesis.
Yamahatsu K; Matsuda Y; Ishiwata T; Uchida E; Naito Z
Int J Oncol; 2012 May; 40(5):1345-57. PubMed ID: 22246533
[TBL] [Abstract][Full Text] [Related]
14. Curcumin inhibits tumor growth and angiogenesis in glioblastoma xenografts.
Perry MC; Demeule M; Régina A; Moumdjian R; Béliveau R
Mol Nutr Food Res; 2010 Aug; 54(8):1192-201. PubMed ID: 20087857
[TBL] [Abstract][Full Text] [Related]
15. Curcumin-ER Prolonged Subcutaneous Delivery for the Treatment of Non-Small Cell Lung Cancer.
Ranjan AP; Mukerjee A; Gdowski A; Helson L; Bouchard A; Majeed M; Vishwanatha JK
J Biomed Nanotechnol; 2016 Apr; 12(4):679-88. PubMed ID: 27301194
[TBL] [Abstract][Full Text] [Related]
16. Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer.
Li L; Ahmed B; Mehta K; Kurzrock R
Mol Cancer Ther; 2007 Apr; 6(4):1276-82. PubMed ID: 17431105
[TBL] [Abstract][Full Text] [Related]
17. Liposome encapsulated curcumin-difluorinated (CDF) inhibits the growth of cisplatin resistant head and neck cancer stem cells.
Basak SK; Zinabadi A; Wu AW; Venkatesan N; Duarte VM; Kang JJ; Dalgard CL; Srivastava M; Sarkar FH; Wang MB; Srivatsan ES
Oncotarget; 2015 Jul; 6(21):18504-17. PubMed ID: 26098778
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release.
Kong G; Anyarambhatla G; Petros WP; Braun RD; Colvin OM; Needham D; Dewhirst MW
Cancer Res; 2000 Dec; 60(24):6950-7. PubMed ID: 11156395
[TBL] [Abstract][Full Text] [Related]
19. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway.
Lin YG; Kunnumakkara AB; Nair A; Merritt WM; Han LY; Armaiz-Pena GN; Kamat AA; Spannuth WA; Gershenson DM; Lutgendorf SK; Aggarwal BB; Sood AK
Clin Cancer Res; 2007 Jun; 13(11):3423-30. PubMed ID: 17545551
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models.
Ferguson D; Rodriguez LE; Palma JP; Refici M; Jarvis K; O'Connor J; Sullivan GM; Frost D; Marsh K; Bauch J; Zhang H; Lin NH; Rosenberg S; Sham HL; Joseph IB
Clin Cancer Res; 2005 Apr; 11(8):3045-54. PubMed ID: 15837760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
